The BCR/ABL oncogene causes chronic myelogenous leukemia (CML) in humans and a CML-like disease, as well as lymphoid leukemia, in mice. p210 BCR/ABL is an activated tyrosine kinase that phosphorylates itself and several cellular signaling proteins. The autophosphorylation site tyrosine 177 binds the adaptor Grb2 and helps determine the lineage and severity of BCR/ABL disease: Tyr177 mutation (BCR/ABL-Y177F) dramatically impairs myeloid leukemogenesis, while diminishing lymphoid leukemogenesis. The critical signal(s) from Tyr177 has remained unclear. We report that Tyr177 recruits the scaffolding adaptor Gab2 via a Grb2/Gab2 complex. Compared to BCR/ABL-expressing Ba/F3 cells, BCR/ABL-Y177F cells exhibit markedly reduced Gab2 tyrosine phosphorylation and association of phosphatidylinositol-3 kinase (PI3K) and Shp2 with Gab2 and BCR/ABL, and decreased PI3K/Akt and Ras/Erk activation, cell proliferation, and spontaneous migration. Remarkably, bone marrow myeloid progenitors from Gab2 (Ϫ/Ϫ) mice are resistant to transformation by BCR/ABL, whereas lymphoid transformation is diminished as a consequence of markedly increased apoptosis. BCR/ABLevoked PI3K/Akt and Ras/Erk activation also are impaired in Gab2 (Ϫ/Ϫ) primary myeloid and lymphoid cells. Our results identify Gab2 and its associated proteins as key determinants of the lineage and severity of BCR/ABL transformation.
Introduction
Shtivelman Walker et al., 1987) . Despite intensive study, the mechanism underlying the different lineage associaSeveral forms of human leukemia are caused by the Philadelphia tions of the three BCR/ABL proteins remains largely unknown. chromosome (Ph) translocation [t(9,22) (q34;q11)], which fuses
The BCR region of the fusion proteins probably plays a the BCR and c-ABL genes. Three different translocation major role in specifying both the virulence and the lineage of breakpoints result in the production of distinct BCR/ABL fusion the leukemia. When introduced into murine bone marrow cells proteins that share the same segment of c-ABL, but differ in by retroviral transduction followed by bone marrow transplanta-BCR content. The most common fusion protein, p210 BCR/ tion (BMT), all of the BCR/ABL fusion proteins can cause a ABL, causes chronic myelogenous leukemia (CML), whereas chronic myeloid leukemia (CML)-like myeloproliferative disease, p190 BCR/ABL is found primarily in a subset of patients with but p190 BCR/ABL is more potent at inducing lymphoid leukeacute lymphocytic leukemia (ALL), and p230 BCR/ABL is found mia (Li et al., 1999; Quackenbush et al., 2000) . Recent studies in chronic neutrophilic leukemia (Ben-Neriah et al., 1986 ; Chan of BCR/ABL oncogenes with mutations of a single autophosphorylation site in BCR, Tyr177, have linked BCR signaling to et Clark et al., 1987; Fainstein et al., 1987; Heisterkamp et al., 1983 Heisterkamp et al., , 1985 Kurzrock et al., 1987; Pane et al., 1996;  lineage determination and disease latency (Million and Van Et-ten, 2000; Zhang et al., 2001) . Tyr177 lies within a Grb2 binding We have found that tyrosine phosphorylation of Gab2 in BCR/ABL-transformed cells requires Y177 of BCR/ABL and the motif (Y-X-N-X) in BCR, and is essential for Grb2 binding to BCR/ ABL (Pendergast et al., 1993; Puil et al., 1994) . The importance of Grb2 SH3 binding site in Gab2; thus, Gab2 phosphorylation by BCR/ABL is mediated by a Grb2/Gab2 complex. This interaction direct binding of Grb2 to BCR/ABL has been controversial. Pendergast et al. reported that p190 BCR/ABL-Y177F is defecis required for full activation of the PI3K/Akt and Ras/Erk pathways and for optimal proliferation and migration of Ba/F3 cells tive for transactivation of a Ras-responsive reporter gene in Rat-1 fibroblasts, transformation of Rat-1 cells to anchoragein response to BCR/ABL. More importantly, BCR/ABL cannot transform primary myeloid cells from Gab2 (Ϫ/Ϫ) mice, whereas independence, and ex vivo transformation of primary bone marrow pre-B lymphocytes. These workers concluded that phosGab2 (Ϫ/Ϫ) B lymphoblasts can be transformed, but exhibit defective migratory capacity and proliferation. The latter is due, phorylation of Tyr177 was necessary for Ras activation and BCR/ABL transformation (Pendergast et al., 1993) . Consistent at least in large part, to a marked increase in apoptosis. Moreover, primary myeloid and lymphoid cells from Gab2 (Ϫ/Ϫ) mice with this hypothesis, expression of a Grb2 SH3 domain dominant-negative mutant (Gishizky et al., 1995) or interference with transduced with BCR/ABL-WT-expressing retroviruses have comparable signaling defects to Ba/F3 cells expressing BCR/ the Ras pathway by expression of activated RasGAP (Sawyers et al., 1995) or dominant-negative Ras  ABL-Y177F. Our results implicate Gab2 as a key mediator of signals critical for determining the lineage and severity of trans- Sakai et al., 1994) inhibits BCR/ABL transformation. However, subsequent studies demonstrated that BCR/ABL-Y177F could formation by BCR/ABL. transform primary B lymphocytes (Goga et al., 1995) and cytokine-dependent hematopoietic cell lines ex vivo (Cortez et al., Results 1995; Goga et al., 1995) . Furthermore, unlike in Rat-1 cells, Ras activation by BCR/ABL-Y177F was normal in hematopoietic cell
The Grb2 binding site in BCR/ABL regulates tyrosine phosphorylation of Gab2 lines , suggesting that Ras could be activated through alternative pathways (e.g., via tyrosine phosphorylated
The binding site for the Grb2 SH2 domain in BCR/ABL (Tyr177) regulates multiple aspects of BCR/ABL action, including ex vivo Shc) in these cells.
Three recent studies have begun to clarify this controversy. transformation of fibroblasts or pre-B lymphocytes and efficient proliferation of factor-dependent hematopoietic cell lines (CorIn the murine bone marrow transduction/transplantation model, p210 BCR/ABL-Y177F is profoundly defective for induction of tez et al., 1995; Pendergast et al., 1993; Puil et al., 1994) , and the latency and type (i.e., lineage) of leukemia caused by BCR/ CML-like myeloproliferative disease; instead, recipients of p210 BCR/ABL-Y177F-transduced marrow succumb to B-and T-lym-ABL in the murine bone marrow transduction/transplantation model (Million and Van Etten, 2000; Zhang et al., 2001 ; He et phoid leukemias of prolonged latency (He et al., 2002; Million and Van Etten, 2000; Zhang et al., 2001 ). These results demonal., 2002) . To identify signaling defects specifically associated with Tyr177, we generated pools of interleukin-3 (IL-3)-depenstrate that Tyr177, and presumably Grb2 binding, contribute to both myeloid and lymphoid leukemogenesis by BCR/ABL, dent murine Ba/F3 cells expressing either wild-type p210 BCR/ ABL (BCR/ABL-WT) or a Tyr177Phe substitution (Y177F) in the although Tyr177 is more important for the former. However, the nature of the signaling pathway downstream of Tyr177 has BCR part of the fusion protein. For comparison, a BCR/ABL construct with a mutation in its CRKL binding site (⌬CRKL), a remained elusive. Because BCR/ABL can stimulate Ras through other mechanisms, at least in hematopoietic cell lines, activated proline-rich region in the ABL part of the fusion protein (Senechal et al., 1996) , and a Grb2/Crkl binding site double mutant Ras may not be the only or even the principal effector of Grb2 in BCR/ABL-expressing cells. Instead, Tyr177, acting via Grb2, (F⌬CRKL), were also used to generate Ba/F3 cell pools. Prolonged growth of BCR/ABL-expressing Ba/F3 cells in the abmay send another signal(s) required for myeloid transformation and important for determining the latency of lymphoid leukemosence of IL-3 can lead to progressive changes in patterns of signal transduction, possibly from the mutagenic effects of BCR/ genesis.
Here we identify the scaffolding adaptor Gab2 as an essen-ABL kinase activity (Nieborowska-Skorska et al., 2000) . We were concerned that some of the discrepancies in the reported effects tial mediator of BCR/ABL transformation. Gab2, a member of the family of PH-domain containing adaptor proteins that includes of BCR/ABL-Y177F (see Introduction) might be caused by such secondary mutations. Therefore, to avoid this potential problem mammalian Gab1 (Holgado-Madruga et al., 1996) and Gab3 (Wolf et al., 2002) and Drosophila DOS (daughter of sevenless) and control for clonal variation, we studied polyclonal cell populations (pools) selected for G418 resistance rather than cytokine- (Herbst et al., 1996; Raabe et al., 1996) , becomes tyrosine phosphorylated in response to a multiple cell stimuli (Gu et al., 1997, independence, and maintained these pools in the presence of IL-3 and the ABL kinase inhibitor STI571 (Gleevec). Cell activa-1998 Cell activa- , 2001 Lynch and Daly, 2002; Miyakawa et al., 2001; Nishida et al., 1999; Wickrema et al., 1999; Zhao et al., 1999) .
tions were initiated by removal of STI571 and IL-3. To ensure that each mutant had the expected phenotype, Reverse genetic and/or genetic analyses implicate Gab2 as a positive (signal-enhancing) component of growth factor, cytowe measured the interaction between Grb2 or Crkl and BCR/ ABL in the Y177F, ⌬CRKL, and F⌬CRKL mutants by immunokine, and antigen receptor signal transduction (Gu et al., 1998 (Gu et al., , 2000 (Gu et al., , 2001 Liu et al., 2001; Lynch and Daly, 2002) , although precipitation followed by immunoblotting ( Figure 1A ). As expected, Grb2 did not coimmunoprecipitate with the BCR/ABL-Y177F and it may have a negative regulatory role in T cell receptor signaling (Pratt et al., 2000; Yamasaki et al., 2001 ). We reported previously -F⌬CRKL mutants, whereas Crkl failed to coprecipitate with BCR/ ABL-⌬CRKL or -F⌬CRKL mutants. We next explored the effects that Gab2 is constitutively tyrosine phosphorylated in BCR/ABLtransformed cells (Gu et al., 1997 (Gu et al., , 1998 . However, its mechaof the Y177F mutation on total cellular tyrosine phosphorylation. Although overall tyrosine phosphorylation was similar in BCR/ nism of phosphorylation and role in BCR/ABL transformation have remained unclear.
ABL-WT-and mutant-expressing cells, cells expressing BCR/ABL- Lysates from 20 ϫ 10 6 cells were subjected to immunoprecipitation with anti-Grb2 or anti-CRKL antibodies, and coimmunoprecipitation of BCR/ABL was assessed by immunoblotting as indicated. The blots were reprobed with anti-Grb2 or anti-CRKL antibodies, as indicated, to control for equal loading. B: The indicated cell lysates (from 0.25 ϫ 10 6 cells) were subjected to anti-phosphotyrosine immunoblotting. The blot was reprobed with anti-Abl and anti-p85-PI3K antibodies, as indicated. Note equal loading of protein (as assessed by p85-PI3K blot) and comparable expression of each BCR/ABL protein. C: Anti-Gab2 immunoprecipitates were prepared from cell lysates as in A, and successively immunoblotted with antibodies against phosphotyrosine, Abl, Gab2, Shp2, and p85-PI3K, as indicated. D-F: Lysates from 20 ϫ 10 6 cells were subjected to immunoprecipitations with antibodies against Abl (D), p85-PI3K (E), or Shp2 (F), followed by immunoblotting with the indicated antibodies. For all panels, the migration positions of molecular mass markers (in kDa) are indicated.
Y177F exhibited distinctly reduced tyrosine phosphorylation of proteins with apparent molecular weights of 40, 72, 100, 120, and 150 kDa. In ⌬CRKL mutant-expressing cells, there was less of an effect on cellular phosphotyrosine proteins, although proteins with apparent molecular weights of 30-40 kDa and a 160 kDa species showed consistent decreases ( Figure 1B , top panel). The pattern of phosphotyrosine-containing proteins in BCR/ABL-F⌬CRKL-expressing cells was the sum of the individual single mutants. Reprobing these immunoblots with anti-ABL and anti-p85-PI3K antibodies confirmed that all of the cell lines expressed comparable levels of BCR/ABL compared to these internal controls ( Figure 1B , middle and bottom panels).
The size and appearance of the 100 kDa phosphotyrosine protein that exhibited decreased phosphorylation in BCR/ABL-Y177F cells were reminiscent of the scaffolding adaptor Gab2. Since Gab2 is phosphorylated in multiple BCR/ABL-WT transformed cell lines, including BCR/ABL-transformed Ba/F3 cells (Gu et al., 1997 (Gu et al., , 1998 , we asked whether the 100 kDa species was Gab2. Indeed, tyrosine phosphorylation of Gab2 was reduced markedly ‫%07ف(‬ as determined by scanning densitometry) in cells expressing BCR/ABL-Y177F or BCR-ABL-F⌬CRKL, but not in cells expressing BCR/ABL-⌬CRKL ( Figure 1C ). Gab2 also coimmunoprecipitated with BCR/ABL-WT and BCR/ABL-⌬CRKL, but to a much lesser extent with BCR/ABL-Y177F (or BCR/ABL-F⌬CRKL) ( Figure 1C and 1D ). Taken together, these results indicate that Tyr177 is required for binding of Gab2 to BCR/ABL and for efficient BCR/ABL-evoked tyrosine phos- 
Gab2 contains binding sites for the SH2 domains of the p85
Gab2 (HA), Abl, Shp2, and PI3K detected by immunoblotting, as indicated.
subunit of PI3K (p85-PI3K) and Shp2. Like Gab2, Shp2 (but For all panels, the migration positions of molecular mass markers (in kDa) not p85-PI3K) is tyrosine phosphorylated constitutively in BCR/ are indicated.
ABL-transformed cells (Gu et al., 1997; Tauchi et al., 1994) . In cells transformed by BCR/ABL-WT or BCR/ABL-⌬CRKL, p85-PI3K and Shp2 were detected in anti-Gab2 ( Figure 1C ) and in anti-ABL ( Figure 1D ) immune complexes. Likewise, Gab2 was Grb2 mediates the interaction of Gab2 with BCR/ABL. Ba/F3, found in anti-p85-PI3K ( Figure 1E ) and anti-Shp2 ( Figure 1F ) Ba/F3.BCR/ABL-WT, and Ba/F3.BCR/ABL-Y177F cell lysates immunoprecipitates. In contrast, Gab2/p85-PI3K and Gab2/ were subjected to immunoprecipitations with anti-Gab2 antiShp2 association, as well as Shp2 tyrosine phosphorylation, bodies, and direct binding of Grb2 was assessed by a protein were reduced dramatically in cells transformed by BCR/ABLoverlay assay. Notably, Gab2 bound to Grb2, and this interac-Y177F, consistent with the substantially decreased Gab2 tyrotion was independent of BCR/ABL-Y177 ( Figure 2A ). sine phosphorylation in these cells ( Figures 1D-1F) . Thus, the Gab2 contains two proline-rich domains that can bind to Y177F mutation causes a marked reduction in Gab2 binding to the Grb2 SH3 domains (Lock et al., 2000) . To determine if the BCR/ABL, decreased tyrosine phosphorylation of Gab2 and the Grb2 SH3 domain binding sites in Gab2 are required for the Gab2-associated signaling protein, Shp2, and reduced binding tyrosine phosphorylation of Gab2, BCR/ABL-WT-expressing of p85-PI3K to Gab2 and BCR/ABL. These findings indicate Ba/F3 cells were transfected transiently with a vector expressing that Gab2 mediates, at least in part, interaction of Shp2 with HA-tagged wild-type Gab2 (Gab2-HA) or a Gab2 mutant lacking BCR/ABL. Moreover, a significant amount of p85-PI3K, and by Grb2 SH3 domain binding sites (Gab2-HA.⌬Grb2). Whereas inference, PI3K (see below) must associate with BCR/ABL via Gab2-HA was robustly tyrosine phosphorylated in response to BCR/ABL, BCR/ABL-evoked tyrosine phosphorylation of Gab2-Gab2.
HA.⌬Grb2 was undetectable. The mutant Gab2 protein also failed to bind to BCR/ABL, Shp2, and PI3K ( Figure 2B ). Thus,
Gab2 is recruited to BCR/ABL via Grb2
Since Tyr177 of BCR is a Grb2 SH2 domain binding site (Pendervia its SH3 domain(s), Grb2 binds to Gab2 constitutively. The Grb2/Gab2 complex is then recruited to BCR/ABL via binding gast et al., 1993; Puil et al., 1994) , and the Grb2 SH3 domains bind Gab2 ( Lysates (25 ϫ 10 6 cells) from Ba/F3 cells or Ba/F3 cells expressing BCR/ABL-WT or BCR/ABL-Y177F, as indicated, were immunoprecipitated with the indicated antibodies, and the resultant immune complexes were subjected to in vitro PI3K kinase assays, followed by thin-layer chromatography and autoradiography. The position of migration of phosphatidylinositol-3 phosphate (as determined by iodine staining of nonradioactive standards) is indicated. PIP3 production, as quantified by scanning densitometry (see Experimental Procedures), was decreased 60%-70% in antiphosphotyrosine immunoprecipitates, 70%-80% in anti-Gab2 immunoprecipitates, and 65%-75% in anti-Abl immunoprecipitates (corresponding to 2-4 experiments with each antibody). B: Tyr177 regulates Akt and Erk activation. Lysates from the indicated cells (0.25 ϫ 10 6 ) were subjected to immunoblotting with phosphospecific antibodies to Akt (p-Akt), Gsk-3␤ (p-Gsk-3␤), and Erk proteins (p-Erk). To control for loading, the blots were stripped and reprobed with antibodies against total Akt (AKT), Gsk-3␤ (GSK-3␤), or Erk1 and Erk2 (ERK1/2). Upon recruitment, Gab2 becomes tyrosine phosphorylated and cells transformed by BCR/ABL-Y177F, PI3K activity associated with anti-phosphotyrosine, anti-ABL, or anti-Gab2 immune recruits additional signal relay molecules, such as Shp2 and p85-PI3K.
complexes was reduced by 60%-80% (see Figure 3A legend ). These results show that Tyr177 is involved in the regulation of PI3K and implicate Gab2 in regulating this activity.
Tyr177 of BCR/ABL regulates multiple downstream
We next asked if Y177 regulates the activation of PI3K efsignaling pathways fectors. Indeed, the serine phosphorylation of Akt and Gsk-3␤ PI3K is known to be activated by BCR/ABL, and is required for was reduced in cells expressing BCR/ABL-Y177F ( Figure 3B ; BCR/ABL transformation of hematopoietic cells (Skorski et al., top and middle panels). Erk 1 and Erk2 activation were also 1995). The reduced binding of p85-PI3K to Gab2 and BCR/ABL diminished in these cells ( Figure 3B , bottom panels). Thus, in BCR/ABL-Y177F-expressing cells suggested that Tyr177
Tyr177-derived signals contribute substantially to the regulation might be involved in the regulation of PI3K activity. Therefore, of multiple downstream signaling pathways known to be critical we measured the PI3K activity associated with anti-phosphotyfor BCR/ABL transformation. rosine, anti-Gab2, and anti-ABL immune complexes ( Figure 3A) . As reported previously , PI3K activity in phosphotyrosine immunoprecipitations was increased in cells tion and Discussion). At least some of these discrepancies may since their ability to be transformed by the TEL/JAK2 oncogene was reduced only slightly (by at most 2-fold; data not shown). have been due to different protocols used to generate BCR/ ABL-expressing hematopoietic cell lines. As indicated above, Overall, our data indicate that Gab2 is required for transformation of murine bone marrow myeloid progenitors by BCR/ABL we made a special effort to limit the exposure of our cell pools to BCR/ABL kinase activity, thereby minimizing potentially muin a colony outgrowth assay, and suggest that at least some of the transforming defects associated with the Y177F mutant are tagenic effects of BCR/ABL. Using this protocol, we compared the effects of BCR/ABL-WT and BCR/ABL-Y177F on several due to failure to transmit appropriate signals through Gab2. Since Gab2 (Ϫ/Ϫ) myeloid cells cannot be stably transdifferent biological responses of Ba/F3 cells. Consistent with previous results , both of these proteins formed by BCR/ABL, extensive biochemical studies of the effects of BCR/ABL in these cells were not possible. Nevertheless, induced factor-independent growth of Ba/F3 cells. However, Ba/F3 cell proliferation in the absence of added cytokines was by making use of retrovirus that coexpresses BCR/ABL-WT and green fluorescence protein (GFP), we were able to infect primary reduced in cells expressing BCR/ABL-Y177F, compared to BCR/ABL-WT ( Figure 3C Figure 4C) ; notably, these defects are qualitatively similar to those observed in BCR/ABL Y177F-expressing Ba/ evoked proliferation. BCR/ABL-WT-transformed Ba/F3 cells demonstrate a significant level of spontaneous migration, as F3 cells (compared to BCR/ABL-WT.Ba/F3) and therefore support the notion that Gab2 is a key transducer of signal(s) from measured in a transwell migration assay (Salgia et al., 1999) . BCR/ABL-Y177F also evoked lower levels of spontaneous miTyr177. gration than BCR/ABL-WT ( Figure 3D ) and, as in the proliferation experiments, the addition of IL-3 rescued the BCR/ABL-Y177F
Gab2 determines the severity of lymphoid transformation by BCR/ABL migration defect. Analogous results were obtained in studies in which BCR/ABL-WT or BCR/ABL-Y177F was expressed in
In the murine bone marrow transduction/transplantation model, BCR/ABL-Y177F exhibits a relative defect in lymphoid leukemo32Dcl3 cells (another IL-3 dependent hematopoietic cell line; data not shown). Thus, signals from Tyr177 contribute to both genic ability (in contrast to its more profound defect in myeloid leukemogenesis; see Introduction). Therefore, we assessed the BCR/ABL-evoked proliferation and migration of hematopoietic cell lines. cells were observed. These cells had the same surface phenotype (B220ϩ/CD24ϩ/BP-1ϩ) as BCR/ABL-transformed Gab2 Importantly, Gab2 (Ϫ/Ϫ) mice have normal steady state hematopoiesis and are otherwise healthy, although their allergic re-(ϩ/ϩ) B lymphoblasts (data not shown). However, when similar numbers of transduced Gab2 (ϩ/ϩ) and Gab2 (Ϫ/Ϫ) bone marsponse is defective (Gu et al., 2001) . Normal myeloid progenitors require cytokines to form colonies in methylcellulose. Consistent row cells were plated, it took significantly longer for the latter to reach confluence ( Figure 5A ). Transduction efficiency of Gab2 with previous work (Gishizky and Witte, 1992) , BCR/ABL-WT, introduced by retroviral transduction, transformed a significant (ϩ/ϩ) and Gab2 (Ϫ/Ϫ) bone marrow was equivalent by determination of proviral copy numbers by Southern blot, and comparanumber of progenitors from Gab2 (ϩ/ϩ) mice, leading to cytokine-independent myeloid colonies (mainly CFU-GM, but a few ble numbers of pre-and pro-B cells from wild-type and mutant bone marrow were GFP positive (data not shown). Thus, Gab2 CFU-M and CFU-GEMM). However, BCR/ABL-WT was completely unable to transform bone marrow cells from Gab2 (Ϫ/Ϫ) (Ϫ/Ϫ) lymphoid cells have a cell autonomous defect in the establishment and/or maintenance of lymphoid transformation. Direct mice ( Figure 4A ). Transduction of bone marrow cells from mice of either genotype with the parental retrovirus did not cause evidence for the latter was provided by measuring the biological properties of pools of BCR/ABL-transformed Gab2 (ϩ/ϩ) and cytokine-independent myeloid colony growth. Notably, in the presence of IL-3, transduced bone marrow cells from Gab2
Gab2(Ϫ/Ϫ) B lymphoblasts. BCR/ABL-transformed Gab2 (Ϫ/Ϫ) cells showed a substantial defect in cell proliferation (Figure (Ϫ/Ϫ) and Gab2 (ϩ/ϩ) mice gave rise to comparable numbers of myeloid colonies, confirming that the bone marrow CFU-C 5B), as well as in spontaneous (i.e., haplotaxis) and chemokineinduced migration ( Figure 5C ). Remarkably, BCR/ABL-evoked content of Gab2 (Ϫ/Ϫ) mice is normal and demonstrating that BCR/ABL is not toxic to Gab2 (Ϫ/Ϫ) progenitors. Moreover, Akt and Erk activation also were defective in transformed Gab2 (Ϫ/Ϫ), compared to Gab2 (ϩ/ϩ), B lymphoblasts ( Figure 5D ). experiments using a green fluorescent protein (GFP)-expressing retrovirus demonstrated that Gab2 (ϩ/ϩ) and Gab2 (Ϫ/Ϫ) bone
To gain further insight into the reason for the defective proliferation of BCR/ABL transformed Gab2 (Ϫ/Ϫ) B lymphoblasts, marrow cells had comparable susceptibility to retroviral transduction ( Figure 4B ). Compared to BCR/ABL-WT, BCR/ABLwe performed cell cycle analysis. Although Gab2 deficiency did not affect the distribution of cells in G1, S, and G2/M, there Y177F was only partially defective at inducing colony outgrowth of Gab2 (ϩ/ϩ) myeloid cells ( Figure 4A ). Importantly, Gab2 (Ϫ/Ϫ) was a marked increase (‫-5ف‬fold) in the percentage of cells with sub-G1 DNA content ( Figures 6A and 6B confirmed by the presence of characteristic DNA laddering in defective BCR/ABL-evoked Erk and Akt activation. To gain insight into which of these pathways might contribute to the inthe Gab2 (Ϫ/Ϫ) cells (data not shown). These data indicate that inability of BCR/ABL to prevent apoptosis probably accounts creased apoptosis in the absence of Gab2, we treated BCR/ ABL-transformed Gab2 (ϩ/ϩ) B lymphoblasts with inhibitors of for the decreased proliferation of Gab2 (Ϫ/Ϫ) B lymphoblasts. Our biochemical analyses indicate that Gab2 (Ϫ/Ϫ) cells exhibit these signaling pathways. The PI3K inhibitor LY294002 and the 3 /well), BCR/ABL-evoked transformation was observed in some Gab2 (ϩ/ϩ) wells, but not in Gab2 (Ϫ/Ϫ) wells. Shown is a representative experiment from three independent assays that yielded comparable results. B: Proliferation of BCR/ABL-transformed Gab2 (ϩ/ϩ) and Gab2 (Ϫ/Ϫ) B lymphoblasts, as measured by [
3 H]-thymidine incorporation. C: BCR/ABL-transformed Gab2 (ϩ/ϩ) and Gab2 (Ϫ/Ϫ) B lymphoblasts were subjected to transwell migration assays in the presence or absence of the chemokine SDF-1␣. D: Akt and Erk activation in BCR/ABL-transformed Gab2 (ϩ/ϩ) and Gab2 (Ϫ/Ϫ) B lymphoblasts was measured by immunoblotting with the indicated phospho-specific antibodies, followed by reprobing for levels of the respective proteins to control for loading.
MEK inhibitor U0126 markedly increased apoptosis of these nals in BCR/ABL transformed B lymphoblasts, and that decreases in these signaling pathways contribute to the increased cells ( Figure 6C ). Similar results were obtained with the MEK inhibitor PD98059 (data not shown). These data suggest that apoptosis and consequently decreased proliferation observed in the absence of Gab2. both the PI3K/Akt and Ras/Erk pathways transmit survival sig-
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CANCER CELL : JUNE 2002 ing PI3K, which is required for Akt activation, and Shp2, which may be important for Erk activation. Akt and Erk both send antiapoptotic signals, and may also contribute to BCR/ABL-evoked migration. Together, these and perhaps other Gab2-generated signals are required for myeloid transformation and contribute to lymphoid transformation, and ultimately leuke- of BCR/ABL-induced leukemia. The BCR autophosphorylation site Tyr177, a Grb2 binding site, is required for transformation of fibroblasts (Pendergast et al., 1993) and for efficient induction of CML-like myeloproliferative disease by BCR/ABL (Million and site for the Grb2 SH2 domain (Pendergast et al., 1993; Puil et Van Etten, 2000; Zhang et al., 2001; He et al., 2002 ). Tyr177 al., 1994 , and the Grb2 SH3 domains associate constitutively also plays a significant, although less profound, role in lymphoid with proline-rich motifs in Gab2 (Gu et al., 1998 (Gu et al., , 2000 Lock et leukemogenesis (Million and Van Etten, 2000; Zhang et al., 2001; al., 2000 ; Figure 2A ), these findings suggested that Gab2 is He et al., 2002) . Whether Grb2 is, indeed, the key Tyr177 binding recruited to, and subsequently phosphorylated by, BCR/ABL protein, as well as the nature of the signaling pathways activated (or a BCR/ABL-associated kinase) via a Grb2/Gab2 complex ( Figure 7) . Consistent with this model, a Gab2 mutant lacking by direct binding of Grb2 to BCR/ABL, has been controversial (see Introduction). Here, using a combined biochemical and Grb2 binding sites is defective in BCR/ABL association, tyrosine phosphorylation, and binding to Shp2 and PI3K ( Figure 2B ). genetic approach, we have identified the scaffolding adaptor protein Gab2, which binds to Grb2, as a critical mediator of the Although a previous study suggested that Shp2 associates directly with BCR/ABL (Tauchi et al., 1994) , our results argue that Tyr177 signal.
We showed previously that, whereas Gab2 becomes tyroShp2 tyrosine phosphorylation and BCR/ABL association are mediated mainly via Gab2. sine phosphorylated in response to a wide variety of cell stimuli, including several hematopoietic cell growth factors and cytoRecruitment via Grb2 is likely to be a general mechanism for activating Dos/Gab family members. In response to ␤c cytokines, it is constitutively tyrosine phosphorylated and associated with signal relay molecules in multiple BCR/ABL-transformed kines, and possibly cytokines that signal via the IL-2 receptor ␤ chain, Gab2 tyrosine phosphorylation is mediated primarily cell lines (Gu et al., 1997 (Gu et al., , 1998 . The results herein show that Gab2 also associates with BCR/ABL, and efficient Gab2 tyrosine by a Shc-Grb2-Gab2 complex (Gu et al., 2000) . The Gab2 relative Gab1 is also recruited to some growth factor receptors via phosphorylation and BCR/ABL association require Tyr177 phosphorylation ( Figures 1C and 1D) . Since Tyr177 is a binding
Grb2 ( study indicates that Gab1 binds to polyoma middle T antigen in experiments such as those in Figure 5A , Gab2 (ϩ/ϩ) cells can yield lymphoid cell transformation, whereas no transformathrough a Shc/Grb2 complex (Ong et al., 2001) . Since Dos/ Gab proteins activate multiple downstream signaling pathways, tion was observed using Gab2 (Ϫ/Ϫ) bone marrow despite equal levels of transduction and prolonged culture (data not shown). signals emanating from Dos/Gab family scaffolds may be as important for Grb2 function as is its ability to recruit Sos to Furthermore, Gab2 (Ϫ/Ϫ) B lymphoblasts have defective haplotaxis and chemotaxis ( Figure 5C ), which also should affect leuactivated receptors. Transforming proteins such as BCR/ABL (and perhaps middle T antigen and others) can subvert this kemic phenotype. We cannot conclude that Gab2 is the only essential downnormal Grb2/Gab2 (or Shc/Grb2/Gab2) signaling pathway. Conceivably, Gab2 plays an important role in the pathogenesis of stream mediator of the Tyr177 signal; other Grb2 binding proteins may be recruited via Y177 and might be required for BCR/ other types of neoplasms as well; notably, a high percentage of breast cancer cell lines and tumors overexpress Gab2 (Daly ABL transformation. The role of such proteins in BCR/ABL transformation, and whether their recruitment is dependent or indeet al., 2002) .
Our work provides compelling evidence that Gab2 is an pendent of Gab2, remains to be determined by genetic analysis. Nevertheless, we favor the notion that Gab2 is the major, if not essential mediator of leukemogenic signals emanating from Tyr177. Cell proliferation and spontaneous migration are imthe only, transforming signal from Tyr177. Whereas Gab2 (Ϫ/Ϫ) myeloid progenitors are refractory to BCR/ABL transformation, paired significantly in BCR/ABL-Y177F Ba/F3 (and 32Dcl3) cells compared to BCR/ABL-WT cells (Figure 3) . Gab2 (Ϫ/Ϫ) and the transforming ability of BCR/ABL-Y177F (for wild-type myeloid cells) is only reduced, not absent. These findings parallel Gab2 (ϩ/ϩ) bone marrow cells yield similar numbers of myeloid colonies in the presence of cytokines ( Figure 4A ), but whereas the marked reduction (but not absence) of Gab2 tyrosine phosphorylation, and the decreased, but not absent, PI3K, Akt, and BCR/ABL-WT gives rise to cytokine-independent myeloid colonies when introduced into Gab2 (ϩ/ϩ) progenitors (Gishizky and Erk activation in BCR/ABL-Y177F-expressing cells, suggesting that a small amount of Gab2 can be tyrosine phosphorylated Witte, 1992; Figure 4A ), Gab2 (Ϫ/Ϫ) progenitors are refractory to BCR/ABL transformation. Several studies indicate a good by alternative means in the absence of Tyr177. Shc is tyrosine phosphorylated in BCR/ABL-expressing cells (Goga et al., correlation between the factor-independent myeloid colony assay and myeloid leukemogenesis by BCR/ABL mutants 1995); conceivably, the residual Gab2 phosphorylation in BCR/ ABL-Y177F cells could be generated via a Shc/Grb2/Gab2 com- (Gross and Ren, 2000; Nieborowska-Skorska et al., 1999; Skorski et al., 1997) . Myeloid leukemogenesis studies (which require plex, as in ␤c cytokine signaling (Gu et al., 2000) . The striking similarity between the effect of Tyr177 mutation on BCR/ABL crossing the Gab2 mutation onto Balb/c background) are in progress in our laboratories.
leukemogenesis in vivo and the consequences of Gab2-deficiency on myeloid and lymphoid transformation ex vivo also Gab2 may be particularly important for myeloid transformation by BCR/ABL, compared to other oncogenic tyrosine kinase argue that Gab2 is the physiologically relevant target of Tyr177. Additional support for this conclusion is provided by the compafusions. Like BCR/ABL, TEL/JAK2 evokes Gab2 tyrosine phosphorylation and association with Shp2 and PI3K (Nguyen et al., rable increase in apoptosis in Gab2 ( 6 ). PI3K activity is required for BCR/ABL transformation (Skorski et al., 1995) , but the mechahave contrasting requirements for Stat5: Stat5 is dispensable for BCR/ABL transformation (Sexl et al., 2000) , but essential for nism of PI3K activation by BCR/ABL has been controversial. BCR/ABL has a consensus binding site (Y-X-X-M) for p85-PI3K, leukemogenesis by TEL/JAK2 (Schwaller et al., 2000) . Thus, different oncogenic-tyrosine kinase fusion proteins may have but mutation of this site does not abrogate PI3K activation or association with BCR/ABL (Jain et al., 1996) . Instead, Skorski distinct transformation requirements, with obvious therapeutic implications.
et al. reported that activation of PI3K by BCR/ABL requires the ABL SH2 domain. These workers found no effect of Tyr177 Gab2 also is an important mediator of lymphoid transformation signals from Tyr177. Remarkably, just as lymphoid leukemutation on BCR/ABL-evoked PI3K activity (Skorski et al., 1997) . In contrast, Roumiantsev et al. found that the SH2 domain mogenesis is affected less severely than myeloid leukemogenesis by Y177F mutation (Million and Van Etten, 2000 ; Zhang of BCR/ABL was dispensable for PI3K activation (Roumiantsev et al., 2001) . The reason for this discrepancy is not clear. Howet al., 2001; He et al., 2002) , the defect in BCR/ABL-evoked transformation of Gab2 (Ϫ/Ϫ) B lymphoblasts is milder than ever, our results show that coimmunoprecipitation of p85-PI3K with BCR/ABL-Y177F is reduced markedly, at least in part bethe (absolute) defect in myeloid transformation by BCR/ABL. Nevertheless, multiple aspects of lymphoid leukemogenesis cause of failure of BCR/ABL-Y177F to bind to Gab2 (Figure 1 ). Moreover, PI3K activity is reduced in anti-phosphotyrosine, antimay be altered in the absence of Gab2. BCR/ABL-transformed B lymphoblasts clearly have a cell autonomous proliferation ABL, and anti-Gab2 immunoprecipitates in cells expressing BCR/ABL-Y177F, and at least two critical targets of the PI3K defect ( Figure 5B ), most likely due to increased apoptosis (Figure 6) ; obviously, such a defect could contribute to the increased pathway, Akt and Gsk-3␤, exhibit decreased activation in these cells (Figure 3 ). These data suggest that Tyr177 is critically latency of lymphoid leukemias evoked by BCR/ABL-Y177F. There probably is an independent defect in establishment of involved in the regulation of PI3K binding and biological activity and implicate Gab2 in BCR/ABL activation of the PI3K/Akt pathlymphoid transformation in Gab2 (Ϫ/Ϫ) mice. If lower numbers of BCR/ABL retrovirus-transduced bone marrow cells are plated way. Consistent with this notion, BCR/ABL-evoked Akt activa-
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Gab2 (ϩ/ϩ) and Gab2 (Ϫ/Ϫ) B lymphoblasts were maintained in RPMI plus tion is diminished in primary myeloid ( Figure 4 ) and lymphoid 20% FCS, antibiotics, and 50 M 2-mercaptoethanol (2-ME).
( Figure 5 ) cells from Gab2 (Ϫ/Ϫ) mice. Notably, Gab2 is also essential for PI3K activation in normal signaling pathways, such (Lock et al., 2000) . In Gab2-HA.⌬GRB2, one of the sites . Nevertheless, our data suggest that the Y177F. Impaired Erk activation ( Figure 5B ), which may reflect MSCVneo p210 (BCR/ABL)-Y177F, and MSCVneo were prepared by tranreduced recruitment of Grb2/Sos and/or reduced signaling sient transfection of 293T cells using the kat ecotropic packaging system, through Gab2 via Shp2-dependent or independent pathways, as described previously (Million and Van Etten, 2000) . All viral stocks had also contributes ( Figure 6C ).
titers of 3 to 5 ϫ 10 6 neomycin-resistant colony-forming units/ml in NIH 3T3
Overall, our results strongly support the concept that the cells and gave rise to equivalent proviral copy numbers in transduced NIH3T3
profound defects in transformation associated with the Y177F or primary bone marrow cells, as determined by Southern blotting. Gab2 (Ϫ/Ϫ) and littermate Gab2 (ϩ/ϩ) mice (129Sv X C57Bl6/J) were described mutation of BCR/ABL are due, in part or in total, to the failure previously (Gu et al., 2001) .
of this mutant to recruit Grb2/Gab2 complex(es), and the subse- Akt, Ras/Erk, and perhaps other, as yet undefined, pathways.
heat-inactivated FCS, 5% (v/v) WEHI-3B conditioned medium, 1 g/ml ciThese defects would significantly impair viability and motility profloxacin, and murine IL-3 (6 ng/ml, Upstate Biotechnology), IL-6 (10 ng/ml, signals from BCR/ABL (Figures 5 and 6 ), consistent with the R&D Systems), and SCF (50 ng/ml, R&D Systems). The next day, cells were ex vivo and in vivo effects of BCR/ABL-Y177F. An additional transferred into 6-well plates, exposed to viral supernatants in prestimulation medium in the presence of 10 mM HEPES (pH 7.5) and 2 g/ml polybrene, implication of our results is that key transforming signals from and centrifuged at 2500 rpm for 90 min at 30ЊC. After adsorption for 4 hr BCR/ABL are mediated by a pathway that is dispensable for at 37ЊC, the medium was changed with fresh prestimulation medium. At 48 normal, basal hematopoiesis. The development of the ABL inhr, a second round of transduction and cosedimentation was performed.
hibitor STI571 has had a dramatic effect on the therapy of CML After a 3 hr adsorption period, the cells were washed once with IMDM, (BCR/ABL disease) (Mauro et al., 2002) . However, it is clear that counted, and plated in triplicate in MethoCult M3234 medium (StemCell resistance to STI571 will limit its therapeutic efficacy (Barthe et Technologies, Vancouver) at 8 ϫ 10ways in transformation by other tyrosine kinase oncogenes. mercaptoethanol). Cultures were scored as transformed when the number of nonadherent cells exceeded 10 6 per ml of culture medium. Similar results
Experimental procedures
were obtained when feeder cells were supplied by Gab2 (ϩ/ϩ) or Gab2 (Ϫ/Ϫ) bone marrow cells. Transformed cells were expanded from these wells Cell culture and maintained as described above. The murine hematopoietic line Ba/F3 was grown in RPMI 1640 with 10% (v/v) fetal calf serum (FCS) and 10% (v/v) WEHI-3B conditioned medium (as Immunoprecipitation and immunoblotting a source of murine IL-3), plus antibiotics (Penicillin/Streptomycin). Pools of Cells were lysed in a buffer containing Tris-HCl (50 mM, pH 8.0), NaCl (150 Ba/F3 cell lines transfected to express BCR/ABL-WT, BCR/ABL-Y177F, mM), NP40 (1% v/v), deoxycholic acid (0.5% w/v), sodium dodecyl sulfate BCR/ABL-⌬CRKL, and BCR/ABL-F⌬CRKL (all in the backbone of p210 BCR/ (0.1% w/v), NaF (100 mM), and glycerol (10% v/v). Immunoprecipitation ABL) were selected for G418 resistance (2 mg/ml). The G418-resistant cells and immunoblotting using a chemiluminescence technique were performed were maintained in Ba/F3 culture medium in the presence of the ABL kinase using standard methods. Tyrosine phosphorylated proteins were detected inhibitor STI571 (1 g/ml) to limit the long-term mutagenic effects of BCR/ using the monoclonal antibody 4G10 (kindly provided by Dr. Brian Druker, ABL. For biochemical experiments, these polyclonal cell lines were grown Oregon Health Science University, Portland, OR). Polyclonal rabbit antisera for 18 hr in the absence of STI571 and WEHI-3B conditioned medium. The against Gab2, Cbl, and Shp2 (Santa Cruz Biotech, Santa Cruz) and mononumber of viable cells was determined by trypan blue exclusion, or total cell clonal anti-HA (12CA5) and ABL (3F12) antibodies were used for immunoblotnumber was determined using a Coulter particle counter (Coulter Counter Z2). Following their generation as described below, BCR/ABL-transformed ting and/or immunoprecipitation. In some studies, phospho-specific antibod- For biochemical analysis of primary myeloid cells, bone marrow was from the American Association for Cancer Research. transduced with MSCV-p210 BCR/ABL-IRES-GFP, and transduced cells were purified by FACS for the GFP fluorophore. Sorted cells were cultured overnight in a cytokine cocktail (mIL-3, mIL-6, and mSCF), and an equal number of live Gab2 (ϩ/ϩ) and Gab2 (Ϫ/Ϫ) cells were depleted of cytokines transformed primary B lymphoid cells obtained from in vitro lymphoid transformation assays were lysed and subjected to immunoblot analysis as de
